Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized Mice

SIMPLE SUMMARY: Current immune checkpoint inhibitors have shown limitations for immunotherapy of prostate cancer. Thus, it is crucial to investigate other immune checkpoints to prevent disease progression in patients with prostate cancer. Here, we first show that the HVEM/BTLA immune checkpoint is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Aubert, Nicolas, Brunel, Simon, Olive, Daniel, Marodon, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235544/
https://www.ncbi.nlm.nih.gov/pubmed/34208480
http://dx.doi.org/10.3390/cancers13123009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235544/
https://www.ncbi.nlm.nih.gov/pubmed/34208480
http://dx.doi.org/10.3390/cancers13123009

Ejemplares similares